{"id":1402,"date":"2014-04-01T12:00:00","date_gmt":"2014-04-01T10:00:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2014\/der-anfang-vom-ende-der-chronischen-hepatitis-c"},"modified":"2022-03-17T14:12:54","modified_gmt":"2022-03-17T13:12:54","slug":"der-anfang-vom-ende-der-chronischen-hepatitis-c","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2014\/der-anfang-vom-ende-der-chronischen-hepatitis-c","title":{"rendered":"Der Anfang vom Ende der chronischen Hepatitis C?"},"content":{"rendered":"<p>Zusammenfassung: Neue Wirkstoffe mit neuen Wirkprinzipien eliminieren bei chronischer Hepatitis C nach den Ergebnissen erster Studien h\u00e4ufiger das Virus als die Standardtherapie mit Interferon alfa plus Ribavirin und Proteasehemmern der ersten Generation (Telaprevir und Boceprevir). Die neuen Wirkstoffe scheinen auch deutlich besser vertr\u00e4glich zu sein als die Proteaseinhibitoren der ersten Generation. Mit der Kombination neuer [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zusammenfassung: Neue Wirkstoffe mit neuen Wirkprinzipien eliminieren bei chronischer Hepatitis C nach den Ergebnissen erster Studien h\u00e4ufiger das Virus als die Standardtherapie mit Interferon alfa plus Ribavirin und Proteasehemmern der ersten Generation (Telaprevir und Boceprevir). Die neuen Wirkstoffe scheinen auch deutlich besser vertr\u00e4glich zu sein als die Proteaseinhibitoren der ersten Generation. Mit der Kombination neuer [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[3354,3348,3357,3351,3352,2893,3355,3347,2401,2892,3350,3356,3353,3349,3360,204,38,3363,3362,3361,3359,3358,1035,3340,3345,3341,3147,3342,3344,2785,3346,3343],"class_list":["post-1402","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-abt-267","tag-abt-072","tag-abt-333","tag-abt-450","tag-alisporivir","tag-asunaprevir","tag-bi-207-127","tag-bms-791325","tag-boceprevir","tag-daclatasvir","tag-danoprevir","tag-deleoprevir","tag-faldaprevir","tag-filibuvir","tag-gs-9256","tag-hepatitis-c","tag-interferon-alfa","tag-lepidasvir","tag-mericitabin","tag-mk-5171","tag-nim-811","tag-peginterferon-alfa","tag-ribavirin","tag-scy-635","tag-setrobuvir","tag-simeprevir","tag-sofosbuvir","tag-sovaprevir","tag-tegobuvir","tag-telaprevir","tag-vaniprevir","tag-vx-222"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1402","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1402"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1402\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1402"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1402"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1402"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}